The effect of additional administration of empagliflozin on patients with linagliptin on renal functio

Not Applicable

Recruiting

• Conditions: type 2 diabetes mellitus

• Registration Number: JPRN-UMIN000029197
• Lead Sponsor: TDE Healthcare Corporation TOSAKI Clinic for Diabetes and Endocrinology

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-09-19
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients who have renal dysfunction (eGFR is less than 30ml/min/1.73m2) 2. Pregnant women 3. Patients judged by the doctor to be ineligible

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
rine albumin creatinine ratio, urin L-FABP.

Secondary Outcome Measures

Name	Time	Method
Glycoalbumin, HbA1c, bodyweight, serum insurin, C-peptide, glucagon, eGFR. Blood glucose transition (standard deviation and MAGE), and average blood glucose level by a Free Style Libre.